Zydus Lifesciences Limited — Dexamethasone Exporter Profile
Indian Pharmaceutical Exporter · #12 for Dexamethasone · $2.6M export value · DGFT Verified
Zydus Lifesciences Limited is the #12 Indian exporter of Dexamethasone with $2.6M in export value and 154 verified shipments. Zydus Lifesciences Limited holds a 1.4% market share in Dexamethasone exports across 6 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Dexamethasone Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Dexamethasone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| KENYA | $1.2M | 71 | 46.4% |
| SOUTH AFRICA | $520.1K | 20 | 20.8% |
| UNITED STATES | $369.0K | 33 | 14.8% |
| UGANDA | $167.8K | 8 | 6.7% |
| YEMEN | $148.8K | 5 | 6.0% |
| YEMEN, DEMOCRATIC | $79.2K | 6 | 3.2% |
| MAURITIUS | $51.4K | 11 | 2.1% |
Zydus Lifesciences Limited exports Dexamethasone to 7 countries. The largest destination is KENYA accounting for 46.4% of Zydus Lifesciences Limited's Dexamethasone shipments, followed by SOUTH AFRICA (20.8%) and UNITED STATES (14.8%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Dexamethasone from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ABACUS PHARMA (AFRICA) LTD | UGANDA | $1.1M | 60 |
| ZYDUS HEALTHCARE SA (PTY) LTD | SOUTH AFRICA | $410.4K | 15 |
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $369.0K | 33 |
| AL-JABAL DRUGS AND MEDICAL APPLIANC | YEMEN, DEMOCRATIC | $141.9K | 8 |
| ABACUS PHARMA AFRICA LTD | KENYA | $100.5K | 6 |
| AL JABAL DRUGS AND MEDICAL APPLIANC | YEMEN | $86.2K | 3 |
| ABACUS PHARMA (AFRICA) LTD., | UGANDA | $85.2K | 4 |
| ZYDUS HEALTHCARE SA (PTY) LIMITED | SOUTH AFRICA | $59.7K | 4 |
| ZYDUS HEALTHCARE SA (PTY) LTD. | SOUTH AFRICA | $50.0K | 1 |
| ABACUS PHARMA (AFRICA) LIMITED | KENYA | $35.7K | 6 |
Zydus Lifesciences Limited supplies Dexamethasone to 14 buyers globally. The largest buyer is ABACUS PHARMA (AFRICA) LTD (UGANDA), followed by ZYDUS HEALTHCARE SA (PTY) LTD (SOUTH AFRICA) and EVERSANA LIFE SCIENCE SERVICES (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Dexamethasone Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $32.1M worth of Dexamethasone through 8,777 shipments from 808 suppliers to 176 countries, serving 2,257 buyers globally. Zydus Lifesciences Limited contributes $2.6M to this total, accounting for 1.4% of India's Dexamethasone exports. Zydus Lifesciences Limited ships Dexamethasone to 7 countries through 14 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Dexamethasone Exports?
Zydus Lifesciences Limited's average Dexamethasone shipment value is $16.8K per consignment, based on 154 shipments totaling $2.6M. The largest destination is KENYA (46.4% of Zydus Lifesciences Limited's Dexamethasone exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Dexamethasone Exporters?
Zydus Lifesciences Limited ranks #12 among 808 Indian Dexamethasone exporters with a 1.4% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($6.1M), SENTISS PHARMA PRIVATE LIMITED ($4.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.3M). Zydus Lifesciences Limited processed 154 shipments to 6 destination countries.
What Dexamethasone Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DEXONA TABLETS 0.5MG (DEXAMETHASONE TABSUSP) 10X10 T | $324.5K | 16 |
| DEXONA TABLETS 0.5MG (DEXAMETHASONE) 10X10 T | $223.2K | 16 |
| DEXONA INJECTION 4MG/ML (DEXAMETHASONE S | $125.6K | 3 |
| DEXONA E/E DROP 5ML (FFS) (DEXAMETHASONE | $93.5K | 3 |
| DEXONA E E DROP 5ML 1 X 5 ML DEXAMETHASONE NEOMYCIN EYE EAR DROPS CONTAINING 0 35 W V NEOMYCIN DEXAMETHASONE SOD | $86.2K | 3 |
| DEXONA E/E DROP 5ML (DEXAMETHASONE & NEOMYCIN EYE/EAR DROPS CONTAINING 0.35% W/VNEOMYCIN & DEXAMETHASONE SODIUM PHOSPHA | $74.7K | 2 |
| DEXONA INJECTION 4MG/ML (DEXAMETHASONE SODIUM 4MG/ML) PACK OF 10X1ML | $50.0K | 1 |
| DEXONA INJECTION 4MG/ML (DEXAMETHASONE SODIUM 4MG/ML) PACK 10X1ML | $50.0K | 1 |
| PHARMA MEDICINE FOR HUMAN USE-DEXONA INJECTION 4MG/ML (DEXAMETHASONE SODIUM 4MG/ML)10X1ML-QTY-48,798.000-AS PER INV | $50.0K | 1 |
| DEXONA E/E DROP (NEOMYCIN SULPHATE ANDDEXAMETHASONE SODIUM PHOSPHATE OPHTHALMIC SOLUTION USP) 5ML | $50.0K | 1 |
Zydus Lifesciences Limited exports 85 distinct Dexamethasone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DEXONA TABLETS 0.5MG (DEXAMETHASONE TABSUSP) 10X10 T with 16 shipments worth $324.5K.
Regulatory Requirements: Exporting Dexamethasone to Key Markets
What Zydus Lifesciences Limited must comply with to export Dexamethasone to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Zydus Lifesciences Limited Compare to Nearest Dexamethasone Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | EUGIA PHARMA SPECIALITIES LIMITED | $3.2M | 64 | 1 | $50.0K |
| 4 | SAKAR HEALTHCARE LIMITED | $2.9M | 57 | 6 | $50.0K |
| 12 | ZYDUS LIFESCIENCES LIMITED ★ | $2.6M | 154 | 6 | $16.8K |
| 1 | DR.REDDY'S LABORATORIES LTD | $2.3M | 46 | 1 | $50.0K |
| 10 | SOMERSET THERAPEUTICS LIMITED | $2.2M | 44 | 1 | $50.0K |
Zydus Lifesciences Limited ranks #12 among 808 Indian Dexamethasone exporters. Average shipment value of $16.8K compared to the market average of $39.8K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and SAKAR HEALTHCARE LIMITED.
Which Indian Ports Ship Dexamethasone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,214 | 13.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,121 | 12.8% |
| NHAVA SHEVA SEA (INNSA1) | 748 | 8.5% |
| DELHI AIR CARGO ACC (INDEL4) | 509 | 5.8% |
| DELHI AIR | 476 | 5.4% |
| JNPT/ NHAVA SHEVA SEA | 472 | 5.4% |
| Bombay Air | 327 | 3.7% |
| JNPT | 320 | 3.6% |
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Dexamethasone Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Dexamethasone, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Dexamethasone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Dexamethasone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 154 individual customs records matching Zydus Lifesciences Limited exporting Dexamethasone, covering 85 formulations to 7 countries via 14 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 176+ countries, 2,257+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Dexamethasone Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Dexamethasone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Dexamethasone Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Dexamethasone. For current shipment-level data, contact TransData Nexus.